Agenus Inc.
Agenus Inc. is classed by the SEC under Biological Products, (No Diagnostic Substances) (industry code 2836), based in Lexington, MA. In its latest annual figures on file, for the fiscal year ended 2025-12-31, it reported revenue of $114 million and a loss of $3 million (its filed statements).
vs its business-model standard
Three tenses, nine metrics. Unseen metrics stay unseen; the grade never fakes a number. Proxy era: provisional values, marked. Weighed as a product business: prior from its industry code (SEC 2836, Biological Products, (No Diagnostic Substances)); the filing read can change it. All three tenses have at least two readings, so the archetype blend applies as printed.
The grade, in three tenses
Headline 4.4 out of ten, 8 of 9 metrics filed and 1 estimated: past 3.3 out of ten, present 5.2 out of ten, future 4.5 out of ten. The past asks what it actually did, the present what it is doing right now, the future what it is set up to do next.
The nine metrics
- Surviving crises (past): 1.2 out of ten. 2 warning events since 2017; the latest 2023-12-08. 12th percentile among 159 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Track record (past): 4.9 out of ten. +19.7% a year over 10 filed years; profitable in 0 of 10. 49th percentile among 102 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Shareholder treatment (past): 3.0 out of ten. CrossAssetData estimate 3.0/10, confidence 35 of 100 (one part). 30th percentile among 146 sector filers. A CrossAssetData estimate, not a filed reading: one part, confidence 35 of 100; a filing that carries the missing parts replaces this estimate with the filed reading.
- Financial health (present): 4.2 out of ten. Leverage 220%: owes 220¢ per asset dollar. 42nd percentile among 147 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Industry position (present): 6.8 out of ten. top 32% of 102 in its family; net margin -0.1%. 68th percentile among 102 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Leadership (present): 5.1 out of ten. top 49% of 108 in its family for leadership; chief executive since 2020. 51st percentile among 108 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-09).
- Room to expand (future): 4.9 out of ten. bottom 49% of 92 in its family for room to expand. 49th percentile among 92 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Growth drivers (future): 2.4 out of ten. bottom 24% of 100 in its family for growth drivers. 24th percentile among 100 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Expectations vs reality (future): 6.7 out of ten. top 33% of 72 in its family for expectations against reality. 67th percentile among 72 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
The filing record
Newest annual report: Form 10-K filed 2026-03-16 for the period ended 2025-12-31 (on EDGAR). Newest quarterly report: Form 10-Q filed 2026-08-07 for the period ended 2026-06-30 (on EDGAR). Newest results release: Form 8-K filed 2026-08-06 (on EDGAR). Newest filing: Form 4, 2026-10-02. Filings on record since 1999. Read from EDGAR 2026-10-12.
Where the revenue comes from
Product and service lines in fiscal 2025: Non Cash Revenue Related to Sale of Future Royalties 94%, Pre Commercial Product Revenue 4%, Revenue 1%, Other 1%, Clinical Product Revenue under 1%, Research and Development Revenue under 1%. By geography: United States 99%, Outside the United States 1%. As tagged in its annual report (Form 10-K, filed 2026-03-16).
Who runs it
Armen, Garo H (Chairman, Chief Executive Officer and Principal Financial Officer); Buell, Jennifer (Chairman of the Executive Counsel); O'Day, Steven J (Chief Medical Officer); Charette, Austin (Principal Accounting Officer); Harrison, Thomas L (director); Wright, Timothy (director); Marcucci, Marco Tullio (director); Corvese, Brian (director); Hirsch, Susan B (director). 9 officers and directors have filed their own trades in the last fifteen months, names and titles as filed with the SEC, through 2026-10-02.
This file: Overview · Past · Present · Future · Filings · every company on file
Every stock is a company. We grade the company behind the stock. CrossAssetData is a company research product: no investment advice, no price targets, no price predictions; every claim carries its source, and unseen means unseen. The full file draws when the page's script runs: the essentials, the balance sheet, the estimators, the trend, and every filing of the last ten years.